A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine
Jose Francis, Simbarashe Zvada, Paolo Denti, Mark Hatherill, Salome Charalambous, Stanley Mungofa, Rodney Dawson, Susan E. Dorman, et al. (16 authors)
Antimicrobial Agents and Chemotherapy · 2019-01
Abstract
rs1803155AA on rifapentine clearance. The observed increase in exposure is modest and unlikely to be of clinical relevance. The difference in bioavailability between the two studies is probably related to the differences in food intake concomitant with the dose. HIV-coinfected patients had lower rifapentine exposures.
MeSH terms
- Rifapentine
- Pharmacokinetics
- Rifamycin
- Pharmacology
- Population
- Medicine
- Rifabutin
- Latent tuberculosis
- Bioavailability
- Concomitant
- Internal medicine
- Tuberculosis
- Antibiotics